KB-1283

Bemarituzumab

×
Please enable JavaScript in your browser to complete this form.
52694
Home » Bemarituzumab

Background of Bemarituzumab

Bemarituzumab, also named FPA-144, is a recombinant IgG1 kappa, human monoclonal antibody produced in CHO cell culture, which can selective bind to FGFR2b. Bemarituzumab is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pathways. Blocking FGFR2b activation is thought to slow cancer progression. Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b.

Specifications

Catalog NumberKB-1283
Antibody NameBemarituzumab
IsotypeHuman IgG1, kappa
FC MuationsWild Type
TargetFGFR2b
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Gemo AT, Deshpande AM, Palencia S, et al: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification. Cancer Res 74, 2014.
Please enable JavaScript in your browser to complete this form.